Leqembi IQLIK (lecanemab-irmb) subcutaneous autoinjector named as one of TIME’s “Best Inventions of 2025” – Eisai + Biogen

Eisai Co., Ltd. and Biogen Inc. announced that Leqembi IQLIK, a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer’s disease (AD) has been selected by TIME as one of the “Best Inventions of 2025” in the Medical and Healthcare category. TIME’s annual list of the Best Inventions features 300 extraordinary innovations changing lives. To compile the 2025 list, TIME solicited nominations from TIME editors and correspondents around the world, and through an online application process, paying special attention to growing fields such as health care and AI. TIME then evaluated each contender on a number of key factors, including originality, efficacy, ambition, and impact. For more information, please visit time.com/collections/best-inventions-2025/.

Leqembi IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and their care partners continue to slow disease progression following the 18-month initial treatment period. The treatment was approved in the U.S. in August 2025 and launched on October 6. Leqembi IQLIK offers patients and their care partners, the potential to shorten administration time (approximate injection time of 15 seconds), providing an option to continue treatment without having to worry about visiting an infusion center. Moreover, it has the potential to reduce healthcare resources associated with intravenous (IV) maintenance dosing, such as preparation for infusion and nurse monitoring, while increasing infusion capacity for new eligible patients to begin initiation treatment and streamlining the overall AD treatment pathway.